Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose-finding study of DII235 in adults with elevated lipoprotein(a)
jRCT2051250158Phase 2Recruiting
- Sponsor
- Novartis
- Start
- Dec 2025
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of BW-20829 in hyperlipoproteinemia and dyslipidemia (5 arms), sponsored by Novartis. Primary endpoints: Time-averaged percentage change from baseline in Lp(a) between Day 60 and Day 180, Difference between DII235 Dose 2 and placebo in time-averaged percent change from baseline in Lp(a) between Day 60 and Day 360 and 1 more. Started Dec 2025; status: recruiting.
02
Drugs
BW-20829
03
Conditions
hyperlipoproteinemiadyslipidemia
Beyond the preview
Go deeper on jRCT2051250158.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051250158.